Overview

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Status:
Unknown status
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Capital Medical University
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria:

- Affected eye has normal IOP

- Not allergic with Avastin